This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogène
This KCNQ3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 651-679 amino acids from the C-terminal region of human KCNQ3.
KCNQ3
Reactivité: Humain, Souris
WB
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
For WB starting dilution is: 1:1000
Restrictions
For Research Use only
Format
Liquid
Concentration
0.45 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
KCNQ3
(Potassium Voltage-Gated Channel, KQT-Like Subfamily, Member 3 (KCNQ3))
anticorps KCNQ3, anticorps si:ch211-66b9.3, anticorps BFNC2, anticorps EBN2, anticorps KV7.3, anticorps potassium voltage-gated channel subfamily Q member 3, anticorps potassium voltage-gated channel, KQT-like subfamily, member 3, anticorps potassium voltage-gated channel, subfamily Q, member 3, anticorps KCNQ3, anticorps kcnq3, anticorps Kcnq3
Sujet
The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and one of two related proteins encoded by the KCNQ2 and KCNQ5 genes, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2).